Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvant therapies after radical cystectomy

BJU International

Volumn 110, Issue 11 B, 2012, Pages

  Lee, Eugene K ^a   Herr, Harry W ^b   Dickstein, Rian J ^a   Kassouf, Wassim ^c   Munsell, Mark F ^a   Grossman, H Barton ^a   Dinney, Colin P N ^a   Kamat, Ashish M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Adjuvant therapy; Bladder cancer; Lymph node density; Radical cystectomy

Indexed keywords

ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYSTECTOMY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE; LYMPH NODE DENSITY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COUNSELING; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SURVIVAL TIME; ADJUVANT CHEMOTHERAPY; ADULT; BLADDER TUMOR; CLINICAL TRIAL; LYMPH NODE METASTASIS; METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; POSTOPERATIVE CARE; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; UNITED STATES;

ADULT; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE CARE; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; URINARY BLADDER NEOPLASMS;

MLCS; MLOWN;

EID: 84876449056     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11325.x     Document Type: Article

References (24)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA-Cancer J Clin 2011 61 : 212-36
2. Jeong IG, Ro JY, Kim SC et al. Extranodal extension in node-positive bladder cancer: the continuing controversy. BJU Int 2011 ; 108 : 38-43
3. Mills RD, Turner WH, Fleischmann A, Markwalder R, Thalmann GN, Studer UE. Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy. J Urol 2001 ; 166 : 19-23
4. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001 ; 19 : 666-75
5. Sternberg CN, Donat SM, Bellmunt J et al. Chemotherapy for bladder cancer: treatment guidelines for neo-sadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 2007 ; 69 : 62-79
6. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996 ; 155 : 495-9 ; discussion 9-500
7. Skinner DG, Daniels JR, Russell CA et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991 ; 145 : 459 - 64 ; discussion 64-7
8. Paz-Ares L, Solsona E, Esteban E et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study (abstract #LBA4518). J Clin Oncol 2010 ; 28 : 18s
9. Stöckle M, Meyenburg W, Wellek S et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 1995 ; 153 : 47-52
10. Herr HW, Faulkner JR, Grossman HB et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol 2004 ; 22 : 2781-9
11. Vieweg J, Gschwend JE, Herr HW, Fair WR. Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J Urol 1999 ; 161 : 449-54
12. Stein JP, Skinner DG. The role of lymphadenectomy in high-grade invasive bladder cancer. Urol Clin North Am 2005 ; 32 : 187-97
13. Kassouf W, Leibovici D, Munsell MF, Dinney CP, Grossman HB, Kamat AM. Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. J Urol 2006 ; 176 : 53-7 ; discussion 7
14. Kassouf W, Agarwal PK, Herr HW et al. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol 2008 ; 26 : 121-6
15. Kassouf W, Svatek RS, Shariat SF et al. Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. Urol Oncol 2011 ; doi: 10.1097/00005392-199501000-00019. epub ahead of print
16. Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 2002 ; 167 : 1295-8
17. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010 ; 17 : 1471-4
18. Eble JNSG, Epstein JI, Sesterhenn IA eds. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. World Health Organization Classification of Tumours. Lyon, France : Lyon IARC Press, 2004
19. Cox DR. Regression models and life tables (with discussion). J R Stat Soc 1972 34 : 187-220
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958 ; 53 : 457-81
21. Schwarz G. Estimating the dimension of a model. Ann Stat 1978 6 : 461-4
22. Gönen M, Heller G. Concordance probability and discriminatory power in proportional hazards regression. Biometrika 2005 92 : 965-70
23. Fleischmann A, Thalmann GN, Markwalder R, Studer UE. Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. J Clin Oncol 2005 ; 23 : 2358-65
24. Cognetti F, Ruggeri EM, Felici A et al. Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomised phase III trial. J Clin Oncol 2008 ; 26 ( Suppl .): abstract 5023